Schuit, Anouk S.
Rienks, Michelle M.
Hooghiemstra, Nienke
Jansen, Femke
Lissenberg-Witte, Birgit I.
Cuijpers, Pim
Verdonck-de Leeuw, Irma M.
Holtmaat, Karen
Funding for this research was provided by:
ZonMw (844001105)
Article History
Received: 3 June 2022
Accepted: 30 October 2022
First Online: 11 November 2022
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and local laws and regulations. The study protocol was approved by the Medical Ethical Committee of VU University Medical Center, Amsterdam, The Netherlands (2018.517).
: The study protocol was approved by the Medical Ethics Committee of VU University Medical Center (2018.517).
: Eligible partners were fully informed about the study and provided written informed consent before participating in the study. Interested partners received an information form about the study and were also informed by phone or in a face-to-face conversation with the researcher. The intervention investigated in this trial was an online self-management application with negligible risks. There was no compensation available for trial participation; partners participating in the study had free access to Oncokompas.
: IMVdL is named as the inventor of Oncokompas, the self-management application that was examined in this study. IMVdL reports grants from the Netherlands Organization for Health Research and Development (ZonMw) (project number: 844001105) and the Dutch Cancer Society (KWF Kankerbestrijding) (project number: VUP2014-7202). The other authors declare no competing interests.